Clearside's Asia-Pacific collaboration partner, Arctic Vision, announced that its New Drug Application (NDA) for ARCATUS ® (known as XIPERE ® in the U.S.) was formally accepted for review by the ...

Cash, cash equivalents and short-term investments were $83.1 million as of March 31, 2025, compared to $125.7 million as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term ...

The “it goes to 11” of marketing copy. This phrase always looks convincing— it's usually written in all caps at the top of ...

Q1 2025 Earnings Call Transcript May 13, 2025 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.55, expectations ...

Q1 2025 Earnings Call Transcript May 13, 2025 Achieve Life Sciences, Inc. beats earnings expectations. Reported EPS is ...

The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is expected to begin patient enrollment in Q2 2025. Additional clinical trial sites in Australia, ...

Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA ...

Richard Stewart; Chief Executive Officer, Director; Achieve Life Sciences Inc Cindy Jacobs; President, Director, Chief Medical Officer; Achieve Life Sciences Inc Mark Oki; Chief Financial Officer; ...

Lawrence Firestone; Chairman of the Board, Chief Executive Officer; 22nd Century Group Inc Daniel Otto; Chief Financial Officer; 22nd Century Group Inc It is now my pleasure to turn the floor over to ...

DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez ...

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...